News | December 31, 2024
Senores Pharmaceuticals IPO lists at 53% premium
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Merck has also decided to end the favezelimab clinical development program
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
The product will be marketed by Dr. Reddy's
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Subscribe To Our Newsletter & Stay Updated
